In a bid to broaden its lung cancer franchise, Zai Lab has entered into a collaboration and license agreement with Mirati Therapeutics to develop and commercialise adagrasib for the treatment of cancer associated with KRAS G12C mutationin Greater China. In preclinical studies, adagrasib has shown to have long half-life and extensive tissue distribution and combination therapies demonstrate increased anti-tumour activity. The deal will accelerate enrolment in key global registration-enabling clinical trials investigating adagrasib in patients with KRAS G12C mutations.